Transformative Biotech is advancing its patented DirectAmp™ extraction‑free PCR buffer and sample‑media platform, which eliminates the nucleic‑acid extraction step from molecular testing. Clinically proven on more than 590,000 patient samples in a high‑volume CLIA‑certified laboratory, the platform delivers faster, more cost‑effective results without compromising gold‑standard PCR accuracy.

We are raising a Seed round to advance 510(k)‑enabling studies, expand independent infectious‑disease validation, and establish OEM partnerships that embed our chemistry into decentralized PCR workflows.

In parallel, we are developing our @ANYWHERE™ lab‑on‑a‑chip device concept to enable future self‑administered, smartphone‑connected molecular testing across infectious‑disease and oncology applications.